Elanco Animal Health, Inc. (ELAN)

Elanco's stock has experienced notable movements in the past six months. As of March 30, 2026, the share price was $23.44, representing a 123.24% increase over the past year. The stock's 52-week range has been between $8.02 and $27.72. Elanco has been described as an "emerging turnaround story" in the animal health sector, with its stock up nearly 70% over the past year. In the fourth quarter of 2025, revenue increased by 12% on a reported basis and 9% organically, driven primarily by new products. Elanco also announced a strategic shift in February 2024 to focus on high-value pet health and livestock sustainability initiatives by selling its aquaculture business to Merck Animal Health for approximately $1.3 billion in cash.

The animal health industry and demand for many of Elanco's products can be affected by weather conditions. Elanco may experience regional and seasonal fluctuations in its results of operations. For example, in 2024, approximately 70% of the total revenue for its higher-margin parasiticide product Seresto and 55% for the Advantage Family was generated in the first half of the year. Historically, May has been the strongest month for Elanco Animal Health Incorporated Common Stock, with an average return of 8.17%.

Elanco Animal Health Incorporated is a global animal health company that develops and delivers products and services for farm animals and pets. The company operates in the pharmaceutical sector, focusing on animal pharmaceuticals, and offers a diverse portfolio of products categorized into Pet Health and Farm Animal. The Pet Health portfolio includes parasiticides, vaccines, and therapeutics, while the Farm Animal portfolio focuses on cattle, swine, and poultry, with products also used in sheep and aquaculture. Elanco also offers digital tools for livestock and pets.

Elanco Animal Health has a significant global presence, supplying its products and services in over 90 countries. The company's headquarters are located in Indianapolis, Indiana, U.S. Elanco is restructuring its global operations, shifting investment towards the U.S. while reducing parts of its overseas footprint, including closing its German animal health R&D facility and implementing targeted reductions to some manufacturing workforce abroad.

Elanco's brand reputation has been impacted by both positive developments and ongoing challenges in the past year. The company has been working to improve its operational efficiency and deliver on its growth strategy. Elanco's focus on innovation, including the launch of new products like Credelio Quattro and Zenrelia, has been highlighted as a driver of growth and positive results. However, Elanco has also faced a significant reputation challenge related to its Seresto flea and tick collar, which has been linked to incidents of pesticide poisoning and pet deaths.

Elanco Animal Health Incorporated has a significant institutional ownership. As of March 31, 2026, institutional shareholders hold 108.43% of Elanco Animal Health stock. Dodge & Cox, Fmr Llc (FMR LLC), and Vanguard Group Inc (The Vanguard Group, Inc.) are major institutional owners. Individual ownership is significantly lower, with insiders owning 10.50% and retail investors 0.00%. Scott D. Ferguson is noted as the largest individual shareholder, owning 27.84 million shares, representing 5.60% of the company.